Nu Skin reported 3Q26 revenue of $311.0M, down 14.6% y/y, while adjusted net income and adjusted EPS were $4.7M and $0.10, respectively. Core Nu Skin revenue declined 19.2%, partially offset by 13.2% growth in Rhyz, while Manufacturing revenue increased 19.3% as delayed orders normalized, though unfavorable mix limited the earnings benefit. Strategic initiatives remain focused on improving sales-force productivity and customer retention, with Prysm iO scan-to-purchase conversion improving to 10% following the latest app update and India now expected to launch in 1H27. Management reduced FY26 revenue guidance to $1.26B–$1.29B and adjusted EPS guidance to $0.55–$0.65, while continued East-West efficiencies, product innovation, and improved channel execution remain central to the 2027 recovery thesis.